ERBB2 and breast cancer: In some breast cancer subtypes, especially HER2-positive patients, early-phase studies indicate that CAR-T cells may provide long-lasting responses; nonetheless, the risk of relapse is still a worry because of the possibility of immune evasion or antigen loss.